Differentiation and reversal of malignant changes in colon cancer through PPARγ

Nature Medicine

Volumn 4, Issue 9, 1998, Pages 1046-1052

  Sarraf, Pasha ^a   Mueller, Elisabetta ^a   Jones, Daniel ^b   King, Frederick J ^a   DeAngelo, Daniel J ^a   Partridge, Jeffrey B ^b   Holden, Sylvia A ^b   Chen, Lan Bo ^a   Singer, Samuel ^c   Fletcher, Christopher ^b   Spiegelman, Bruce M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRL 46593; CARCINOEMBRYONIC ANTIGEN; IBUPROFEN; INDOMETACIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; CHROMANS; COLONIC NEOPLASMS; GENE EXPRESSION; HUMANS; LIGANDS; MICE; MICE, NUDE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0031671246     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/2030     Document Type: Article

References (31)

1. Mangelsdorf, D.J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835-839 (1995).
2. Spiegelman, B.M. & Flier, J.S. Adipogenesis and obesity: rounding out the big picture. Cell 87, 377-389 (1996).
3. Lehmann, J.M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 270, 12953-12956 (1995).
4. Lehmann, J.M., Lenhard, J.M., Oliver, B.B., Ringold, G.M. & Kliewer, S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272, 3406-3410 (1997).
5. Kliewer, S.A. et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83, 813-819 (1995).
6. Forman, B.M. et al. 15-deoxy-Delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83, 803-812 (1995).
7. Kliewer, S.A. et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptor alpha and gamma. Proc. Natl. Acad. Sci. USA 94, 4318-4323 (1997).
8. Altiok, S., Xu, M. & Spiegelman, B.M. PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA binding activity via downregulation of PP2A. Genes Dev. 11, 1987-1998 (1997).
9. Tontonoz, P. et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor-gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. USA 94, 237-241 (1997).
10. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. & Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82 (1998).
11. Jiang, C., Ting, A.T. & Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86 (1998).
12. Mansen, A., Guardiola-Diaz, H., Rafter, J., Branting, C. & Gustafsson, J.A. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem. Biophys. Res. Commun. 222, 844-851 (1996).
13. Auboeuf, D. et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46, 1319-1327 (1997).
14. DuBois, R.N. et al. The Nuclear Eicosanoid Receptor, PPARγ, is aberrantly expressed in Colonic Cancers. Carcinogenesis 19, 49-53 (1998).
15. Menck, H.R. et al. Clinical highlights from the National Cancer Data Base:1997. CA Cancer J. Clin. 47, 161-170 (1997).
16. Chantret, I., Barbat, A., Dussaulx, E., Brattain, M.G. & Zweibaum, A. Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res 48, 1936-1942 (1988).
17. Kawai, K. et al. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 47, 356-368 (1997).
18. Thomas, P. in Metastatic Potential of Human Colorectal Cancer Cell Lines, 1-94 (R. G. Landes, Austin, Texas, 1993).
19. Kondoh, N., Schweinfest, C.W., Henderson, K.W. & Papas, T.S. Differential expression of S19 ribosomal protein, laminin-binding protein, and human lymphocyte antigen class 1 messenger RNAs associated with colon carcinoma progression and differentiation. Cancer Res. 52, 791-796 (1992).
20. Zhang, L. et al. Gene expression profiles in normal and cancer cells. Science 276, 1268-1272 (1997).
21. Mafune, K. et al. Expression of a Mr 32,000 laminin-binding protein messenger RNA in human colon carcinoma correlates with disease progression. Cancer Res. 50, 3888-3891 (1990).
22. Tomlinson, I.P. & Bodmer, W.F. Failure of programmed cell death and differentiation as causes of tumors: some simple mathematical models. Proc. Natl. Acad. Sci. USA 92, 11130-11134 (1995).
23. Kinzler, K.W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
24. Kohl, N.E. et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA 91, 9141-9145 (1994).
25. Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. & Saltiel, A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92, 7686-7689 (1995).
26. Selivanova, G. et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med 3, 632-638 (1997).
27. Gordon, J.I., Schmidt, G.H. & Roth, K.A. Studies of intestinal stem cells using normal, chimeric, and transgenic mice. FASEB J 6, 3039-3050 (1992).
28. Hu, E., Kim, J.B., Sarraf, P. & Spiegelman, B.M. Inhibition of adipogenesis through MAP Kinase-mediated phosphorylation of PPARgamma. Science 274, 2100-2103 (1996).
29. Mueller, E. et al. Terminal Differentiation of Human Breast Cancer through PPARγ. Molecular Cell 1, 465-470 (1998).
30. Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M. & Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331, 1188-1193 (1994).
31. Levy, G.N. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 11, 234-247 (1997).